After spinal cord injury, oxidative stress, inflammation, and mitochondrial dysfunction can cause neural damage that was once believed to be both immediate and irreversible. However, neuronal death is now believed to proceed over a period of several days after initial trauma, and to include cellular, molecular, and biochemical cascades, including local inflammatory responses. Tumor necrosis factor is believed to be involved in the local production of cytokines at the site of the injury.
After spinal cord injury, oxidative stress, inflammation, and mitochondrial dysfunction can cause neural damage that was once believed to be both immediate and irreversible. However, neuronal death is now believed to proceed over a period of several days after initial trauma, and to include cellular, molecular, and biochemical cascades, including local inflammatory responses. Tumor necrosis factor (TNF) is believed to be involved in the local production of cytokines at the site of the injury.
In a study recently published in the Asian Journal of Neurosurgery, researchers sought to assess whether the anti-TNF agent etanercept could have neuroprotective effects following spinal cord injury.
The investigators conducted their study in 54 rats, randomly assigned to undergo either skin incision (from which nonischemic spinal cord samples were obtained), spinal cord trauma followed by spinal cord sampling, or spinal cord trauma followed by immediate administration of a single dose of etanercept (at a dose of 5 mg/kg) and spinal cord sampling. Samples were obtained from the rats in each of the 3 groups at 1 hour (n = 6), 6 hours (n = 6), and 24 hours (n = 6).
The researchers found that levels of the pro-inflammatory cytokine interleukin1-beta (IL-1β) levels were lower in rats in the etanercept group at 1 hour and 6 hours after injury, and spinal tissue catalase (an antioxidative enzyme) levels were significantly higher in the etanercept group at 6 hours, versus the trauma-only group. Spinal tissue levels of TNF alpha and malondialdehyde (a lipid peroxidation product that increases immediately after spinal cord injury) were significantly lower in the etanercept group than in the trauma group at hours 1 and 6.
Histopathological grades of trauma in the etanercept group were improved versus the trauma-alone group, though the histopathological grades of the etanercept group were higher at 24 hours than they were at 6 hours. Thus, say the authors, a single dose of etanercept may not be sufficient to maintain its benefits through 24 hours post-injury.
The authors conclude that etanercept decreased TNF and IL-1β levels while increasing antioxidative enzymes at 1 hour and 6 hours, and that early administration of etanercept may help to reduce histopathological damage that occurs after spinal cord injury.
Reference
Hasturk AE, Baran C, Yilmaz ER, et al. Etanercept prevents histopathological damage after spinal cord injury in rats. Asian J Neurosurg. 2018;13(1):37-45. doi: 10.4103/ajns.AJNS_307_16.
Physician and Patient Perspectives After Starting or Switching to Amgevita in IBD
March 23rd 2024A real-world study surveying physicians and patients on adalimumab biosimilar ABP 501 (Amgevita) in inflammatory bowel disease (IBD) found both patients initiating ABP 501 and those who had switched from the reference product had higher satisfaction levels.
What AmerisourceBergen's Report Reveals About Payers, Biosimilar Pricing Trends
May 28th 2023On this episode of Not So Different, Tasmina Hydery and Brian Biehn from AmerisourceBergen discussed results from a recent survey, that were also presented at Asembia 2023, diving into the payer perspective on biosimilars and current pricing trends across the US biosimilar industry.
The Role of Biosimilars: Advancing Access, Financial Health, and System Sustainability
March 11th 2024Kashyap Patel, MD, CEO of Carolina Blood and Cancer Care, a member of the Community Oncology Alliance, and member of The Center for Biosimilars® Advisory Board, glances back at the development of the biosimilar industry and the last 5 years of progress.
Pipelines and Preparation: How the US Can Prepare for More RA Biosimilars
April 16th 2023What can practices do to prepare for all the biosimilars to treat rheumatoid arthritis (RA) coming down the pipeline? And how can they ensure that the lower-than-anticipated adoption rates for infliximab biosimilars are not repeated? Robert Zutaut, RPh, from McKesson Provider Solutions, tackles all this and more on this episode of Not So Different.
Cardinal Health Report Showcases Biosimilar Growth, Provider and Payer Evolution, and More
February 29th 2024In its annual biosimilars report, Cardinal Health provided updates on how provider acceptance growth, evolving payer dynamics, and the growing pipeline for biosimilars will shape the biosimilar landscape over the next 5 years.
Biosimilar Substitution Within OCM Could Result in Lower Total Cost of Care
February 16th 2024Researchers found that the total cost of care per oncology episode was significantly lowered when biosimilar substitution was implemented in Medicare’s Oncology Care Model (OCM), suggesting that biosimilar uptake can serve as a critical tool to mitigate risk and improve financial performance for providers.